IFNB1 and myeloid sarcoma: The presence of circulatory JCPyV miRNAs in JCPyV-seronegative MS patients was also confirmed in a recent work on patients treated with Natalizumab and interferon-beta, in whom miR-J1-5p was measured directly from plasma [53].